Research
TSLA Robotaxi Launch: Revenue Could Hit $8B by 2028 — But Execution Risk Is Real
Natera's SEC 8-K executive change highlights board strengthening, setting up strategic updates on the next earnings call amid 36% revenue growth, margin expansion to 65%, and $2.6B+ 2026 guidance. Oncology MRD leadership positions NTRA for outperformance despite recent share weakness.